Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2003

View Archived Issues

Spotlight on endometriosis

AlphaVax receives new award from NIAID

Celera Diagnostics enters research collaboration with Merck & Co.

Discovery Partners and Inspire expand collaboration

Lexicon reviews gene knockouts to predict efficacy of new drugs

MethylGene and Taiho enter HDAC inhibitor collaboration

New antiherpesvirus agents prepared and tested at GSK

Curacyte claims novel urokinase inhibitors with utility in cancer therapy

Roche describes new AKT inhibitors as potential propapoptotic antitumor agents

Dual NO donors/antioxidants and their use in syndrome X and other disorders

New sGC activators for erectile dysfunction claimed by Abbott researchers

Merck Frosst and AxyS patent describes new cathepsin K inhibitors

Novel protein kinase inhibitors identified by Vertex scientists

Topical microbicides safe in healthy and HIV-infected men

Ferumoxtran-10 improves detection of nodal metastases by MRI

Topiramate improves body composition and blood pressure of obese patients

Acorda awarded grants to support research in extracellular matrix modification

Once-weekly Enbrel approved

Phase II OSCAR trial evaluates AGIX-4207 for rheumatoid arthritis

Approvable letter issued for expansion of Provigil labeling

Dose-related performance improvement with CX-516 after sleep deprivation

Phase III program evaluates milnacipran for FMS

Positive preliminary results announced for tolevamer in C. difficile diarrhea

Keryx initiates phase II/III program of KRX-101 for diabetic nephropathy

Encouraging preliminary phase II results for ThGRF in COPD wasting

Vion licenses Triapine rights in China, Taiwan, Hong Kong and Macao

Novel antiplatelet/antithrombotic agent acting through the L-arginine/NO pathway

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...